Lv7
5000 积分 2022-08-11 加入
Navigating the clinical progress of antibody-drug conjugates: Emerging opportunities and remaining challenges
1天前
已完结
Industry Perspective on First‐in‐Human and Clinical Pharmacology Strategies to Support Clinical Development of T‐Cell Engaging Bispecific Antibodies for Cancer Therapy
1个月前
已完结
Phase 2b Trial of a Na V 1.8 Inhibitor for Acute Pain
1个月前
已完结
The next generation of antibody–drug conjugates
1个月前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
6个月前
已完结
Fifty years of monoclonals: the past, present and future of antibody therapeutics
8个月前
已完结
Clinical Translation of Targeted Protein Degraders
9个月前
已完结
Nonclinical teratogenicity safety assessment of CRBN-engaging targeted protein degraders: Points to consider
9个月前
已完结
What Is the Potential Relevance of Growth and Differentiation Factor-15 in Neurologic Disease?
11个月前
已完结
The state of the art in secondary pharmacology and its impact on the safety of new medicines
1年前
已完结
皖公网安备34019202002308
